Janux Therapeutics Inc - Asset Resilience Ratio
Janux Therapeutics Inc (JANX) has an Asset Resilience Ratio of 87.97% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check JANX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Janux Therapeutics Inc's Asset Resilience Ratio has changed over time. See Janux Therapeutics Inc (JANX) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Janux Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Janux Therapeutics Inc (JANX) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $904.56 Million | 87.97% |
| Total Liquid Assets | $904.56 Million | 87.97% |
Asset Resilience Insights
- Very High Liquidity: Janux Therapeutics Inc maintains exceptional liquid asset reserves at 87.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Janux Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Janux Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Janux Therapeutics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Janux Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 90.74% | $914.23 Million | $1.01 Billion | +34.73pp |
| 2024-12-31 | 56.01% | $594.57 Million | $1.06 Billion | -29.38pp |
| 2023-12-31 | 85.39% | $324.82 Million | $380.41 Million | +9.68pp |
| 2022-12-31 | 75.71% | $275.59 Million | $364.01 Million | -13.64pp |
| 2021-12-31 | 89.35% | $339.38 Million | $379.82 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $16.22 Million | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more